Viewing Study NCT04335292


Ignite Creation Date: 2025-12-24 @ 3:25 PM
Ignite Modification Date: 2025-12-29 @ 12:52 PM
Study NCT ID: NCT04335292
Status: RECRUITING
Last Update Posted: 2024-10-22
First Post: 2020-03-06
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer with Osimertinib Third-line Rechallenge
Sponsor: Mark Vincent
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module